carlisle medical
Refill Requests shipment tracking contact carlisle medical
Knowledge Center
Industrial related news
FDA Approves New Extended-Release Oxycodone with Abuse-Deterrent Properties
Released: 07/23/2014
By: Carl Richie, Pharmacy Manager

"Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the product’s abuse-deterrent properties consistentwith the FDA’s 2013 draft guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling.

Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection. When crushed and snorted, or crushed, dissolved and injected, the naloxone in Targiniq ER blocks the euphoric effects of oxycodone, making it less liked by abusers than oxycodone alone. Naloxone is a medication that is commonly used to reverse the effects of opioid overdose. Targiniq ER can still be abused, including when taken orally (by mouth), which is currently the most common way oxycodone is abused. It is important to note that taking too much Targiniq ER for purposes of abuse or by accident, can cause an overdose that can result in death."¹

Note:¹ Excerpted from FDA News Release from July 23, 2014

<<Back
 
Company News
Generic Releases
Industry Related News
Industry Related Links
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2018 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer